<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327222</url>
  </required_header>
  <id_info>
    <org_study_id>LOW-VISION</org_study_id>
    <nct_id>NCT01327222</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)</brief_title>
  <acronym>LOW-VISION</acronym>
  <official_title>Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of intravitreal bevacizumab
      injection (IVBI) with respect to simple observation in patients with subfoveal choroidal
      neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at
      baseline with best corrected visual acuity (BCVA) less than 20/200.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no clear indication regarding the treatment of patients with subfoveal choroidal
      neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at
      baseline with best corrected visual acuity (BCVA) less than 20/200.

      Treatment of eyes with low visual acuity could lead to a waste of resources, without any
      functional and social improvements.

      Aim of the present study is to compare the effectiveness of intravitreal bevacizumab
      injection (IVBI) with respect to simple observation in
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in best-corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>change in best-corrected visual acuity at the end of the follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in central macular thickness</measure>
    <time_frame>6 months</time_frame>
    <description>change in central macular thickness on OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEI VFQ-25 scores</measure>
    <time_frame>6 months</time_frame>
    <description>change in NEI VFQ-25 scores questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>monthly follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>1.25 mg intravitreal bevacizumab</description>
    <arm_group_label>bevacizumab</arm_group_label>
    <other_name>avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age-related macular degeneration

          -  naïve subfoveal choroidal neovascularization

          -  best-corrected visual acuity less then 20/200

        Exclusion Criteria:

          -  previous treatments

          -  any other condition able to limit the visual improvement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Bandello, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, Maia M, Farah ME, Brito M, Díaz-Llopis M, Rodríguez FJ, Reategui G, Iturralde-Iraola J, Udaondo-Mirete P; Pan-American Collaborative Retina Study Group. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Ophthalmology. 2010 Oct;117(10):1974-81, 1981.e1. doi: 10.1016/j.ophtha.2010.01.056. Epub 2010 May 31.</citation>
    <PMID>20569989</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Francesco Bandello</name_title>
    <organization>Department of Ophthalmology</organization>
  </responsible_party>
  <keyword>age-related macular degeneration</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

